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Sabatino Maione4, Aldo Laganà2,5, Anna Laura capriotti5, Flavio forni3, 
Maria Angela Vandelli3, Giuseppe Gigli2 & Giuseppe cannazza  2,3*
(-)-Trans-Δ9-tetrahydrocannabinol (Δ9-THC) is the main compound responsible for the intoxicant 
activity of Cannabis sativa L. The length of the side alkyl chain influences the biological activity 
of this cannabinoid. In particular, synthetic analogues of Δ9-tHc with a longer side chain have 
shown cannabimimetic properties far higher than Δ9-THC itself. In the attempt to define the 
phytocannabinoids profile that characterizes a medicinal cannabis variety, a new phytocannabinoid 
with the same structure of Δ9-THC but with a seven-term alkyl side chain was identified. The natural 
compound was isolated and fully characterized and its stereochemical configuration was assigned by 
match with the same compound obtained by a stereoselective synthesis. This new phytocannabinoid 
has been called (-)-trans-Δ9-tetrahydrocannabiphorol (Δ9-tHcp). Along with Δ9-THCP, the 
corresponding cannabidiol (cBD) homolog with seven-term side alkyl chain (cBDp) was also isolated 
and unambiguously identified by match with its synthetic counterpart. The binding activity of Δ9-tHcp 
against human CB1 receptor in vitro (Ki = 1.2 nM) resulted similar to that of CP55940 (Ki = 0.9 nM), a 
potent full CB1 agonist. In the cannabinoid tetrad pharmacological test, Δ9-THCP induced hypomotility, 
analgesia, catalepsy and decreased rectal temperature indicating a THC-like cannabimimetic activity. 
The presence of this new phytocannabinoid could account for the pharmacological properties of some 
cannabis varieties difficult to explain by the presence of the sole Δ9-tHc.
Cannabis sativa has always been a controversial plant as it can be considered as a lifesaver for several pathologies 
including glaucoma1 and epilepsy2, an invaluable source of nutrients3, an environmentally friendly raw material 
for manufacturing4 and textiles5, but it is also the most widely spread illicit drug in the world, especially among 
young adults6.
Its peculiarity is its ability to produce a class of organic molecules called phytocannabinoids, which derive 
from an enzymatic reaction between a resorcinol and an isoprenoid group. The modularity of these two parts is 
the key for the extreme variability of the resulting product that has led to almost 150 different known phytocan-
nabinoids7. The precursors for the most commonly naturally occurring phytocannabinoids are olivetolic acid and 
geranyl pyrophosphate, which take part to a condensation reaction leading to the formation of cannabigerolic 
acid (CBGA). CBGA can be then converted into either tetrahydrocannabinolic acid (THCA) or cannabidiolic 
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acid (CBDA) or cannabichromenic acid (CBCA) by the action of a specific cyclase enzyme7. All phytocannabi-
noids are biosynthesized in the carboxylated form, which can be converted into the corresponding decarboxy-
lated (or neutral) form by heat8. The best known neutral cannabinoids are undoubtedly Δ9-tetrahydrocannabinol 
(Δ9-THC) and cannabidiol (CBD), the former being responsible for the intoxicant properties of the cannabis 
plant, and the latter being active as antioxidant, anti-inflammatory, anti-convulsant, but also as antagonist of THC 
negative effects9.
All these cannabinoids are characterized by the presence of an alkyl side chain on the resorcinyl moiety made 
of five carbon atoms. However, other phytocannabinoids with a different number of carbon atoms on the side 
chain are known and they have been called varinoids (with three carbon atoms), such as cannabidivarin (CBDV) 
and Δ9-tetrahydrocannabivarin (Δ9-THCV), and orcinoids (with one carbon atom), such as cannabidiorcol 
(CBD-C1) and tetrahydrocannabiorcol (THC-C1)7. Both series are biosynthesized in the plant as the specific 
ketide synthases have been identified10.
Our research group has recently reported the presence of a butyl phytocannabinoid series with a four-term 
alkyl chain, in particular cannabidibutol (CBDB) and Δ9-tetrahydrocannabutol (Δ9-THCB), in CBD samples 
derived from hemp and in a medicinal cannabis variety11,12. Since no evidence has been provided for the presence 
of plant enzymes responsible for the biosynthesis of these butyl phytocannabinoids, it has been suggested that 
they might derive from microbial ω-oxidation and decarboxylation of their corresponding five-term homologs13.
The length of the alkyl side chain has indeed proved to be the key parameter, the pharmacophore, for the bio-
logical activity exerted by Δ9-THC on the human cannabinoid receptor CB1 as evidenced by structure-activity 
relationship (SAR) studies collected by Bow and Rimondi14. In particular, a minimum of three carbons is neces-
sary to bind the receptor, then the highest activity has been registered with an eight-carbon side chain to finally 
decrease with a higher number of carbon atoms14. Δ8-THC homologs with more than five carbon atoms on the 
side chain have been synthetically produced and tested in order to have molecules several times more potent than 
Δ9-THC15,16.
To the best of our knowledge, a phytocannabinoid with a linear alkyl side chain containing more than five 
carbon atoms has never been reported as naturally occurring. However, our research group disclosed for the first 
time the presence of seven-term homologs of CBD and Δ9-THC in a medicinal cannabis variety, the Italian FM2, 
provided by the Military Chemical Pharmaceutical Institute in Florence. The two new phytocannabinoids were 
isolated and fully characterized and their absolute configuration was confirmed by a stereoselective synthesis. 
According to the International Non-proprietary Name (INN), we suggested for these CBD and THC analogues 
the name “cannabidiphorol” (CBDP) and “tetrahydrocannabiphorol” (THCP), respectively. The suffix “-phorol” 
comes from “sphaerophorol”, common name for 5-heptyl-benzen-1,3-diol, which constitutes the resorcinyl moi-
ety of these two new phytocannabinoids.
A number of clinical trials17–19 and a growing body of literature provide real evidence of the pharmacological 
potential of cannabis and cannabinoids on a wide range of disorders from sleep to anxiety, multiple sclerosis, 
autism and neuropathic pain20–23. In particular, being the most potent psychotropic cannabinoid, Δ9-THC is the 
main focus of such studies. In light of the above and of the results of the SAR studies14–16, we expected that THCP 
is endowed of an even higher binding affinity for CB1 receptor and a greater cannabimimetic activity than THC 
itself. In order to investigate these pharmacological aspects of THCP, its binding affinity for CB1 receptor was 
tested by a radioligand in vitro assay and its cannabimimetic activity was assessed by the tetrad behavioral tests 
in mice.
Results
Identification of cannabidiphorol (CBDP) and Δ9-tetrahydrocannabiphorol (Δ9-THCP) by liquid 
chromatography coupled to high-resolution mass spectrometry (LC-HRMS). The FM2 ethanolic 
extract was analyzed by an analytical method recently developed for the cannabinoid profiling of this medicinal 
cannabis variety12,24. As the native extract contains mainly the carboxylated forms of phytocannabinoids as a 
consequence of a cold extraction25, part of the plant material was heated to achieve decarboxylation where the 
predominant forms are neutral phytocannabinoids. The advanced analytical platform of ultra-high performance 
liquid chromatography coupled to high resolution Orbitrap mass spectrometry was employed to analyze the FM2 
extracts and study the fragmentation spectra of the analytes under investigation. The precursor ions of the neutral 
derivatives cannabidiphorol (CBDP) and Δ9-tetrahydrocannabiphorol (Δ9-THCP), 341.2486 for the [M-H]− and 
343.2632 for the [M + H]+, showed an elution time of 19.4 min for CBDP and 21.3 min for Δ9-THCP (Fig. 1a). 
Their identification was confirmed by the injection of a mixture (5 ng/mL) of the two chemically synthesized 
CBDP and Δ9-THCP (Fig. 1b) as it will be described later. As for their carboxylated counterpart, the precursor 
ions of the neutral forms CBDP and Δ9-THCP break in the same way in ESI+ mode, but they show a different 
fragmentation pattern in ESI− mode. Whilst Δ9-THCP shows only the precursor ion [M-H]− (Fig. 1d), CBDP 
molecule generates the fragments at m/z 273.1858 corresponding to a retro Diels-Alder reaction, and 207.1381 
corresponding to the resorcinyl moiety after the break of the bond with the terpenoid group (Fig. 1c). It is note-
worthy that for both molecules, CBDP and Δ9-THCP, each fragment in both ionization modes differ exactly by 
an ethylene unit (CH2)2 from the corresponding five-termed homologs CBD and THC. Moreover, the longer 
elution time corroborates the hypothesis of the seven-termed phytocannabinoids considering the higher lipo-
philicity of the latter.
Isolation and characterization of natural CBDP and Δ9-tHcp. In order to selectively obtain a 
cannabinoid-rich fraction of FM2, n-hexane was used to extract the raw material instead of ethanol, which car-
ries other contaminants such as flavonoids and chlorophylls along with cannabinoids26. An additional dewaxing 
step at −20 °C for 48 h and removal of the precipitated wax was necessary to obtain a pure cannabinoids extract. 
Semi-preparative liquid chromatography with a C18 stationary phase allowed for the separation of 80 fractions, 
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which were analyzed by LC-HRMS with the previously described method. In this way, the fractions contain-
ing predominantly cannabidiphorolic acid (CBDPA) and tetrahydrocannabipgorolic acid (THCPA) were sepa-
rately subject to heating at 120 °C for 2 h in order to obtain their corresponding neutral counterparts CBDP and 
Δ9-THCP as clear oils with a >95% purity. The material obtained was sufficient for a full characterization by 1H 
and 13C NMR, circular dichroism (CD) and UV absorption.
Stereoselective synthesis of cBDp and Δ9-tHcp. (-)-trans-Cannabidiphorol ((-)-trans-CBDP) 
and (-)-trans-Δ9-tetrahydrocannabiphorol ((-)-trans-Δ9-THCP) were stereoselectively synthesized as pre-
viously reported for the synthesis of (-)-trans-CBDB and (-)-trans-Δ9-THCB homologs11,12,24. Accordingly, 
(-)-trans-CBDP was prepared by condensation of 5-heptylbenzene-1,3-diol with (1 S,4 R)-1-methyl-4-(prop-
1-en-2-yl)cycloex-2-enol, using pTSA as catalyst, for 90 min. Longer reaction time did not improve the yield of 
(-)-trans-CBDP because cyclization of (-)-trans-CBDP to (-)-trans-Δ9-THCP and then to (-)-trans-Δ8-THCP 
occurred. 5-heptylbenzene-1,3-diol was synthesized first as reported in the Supporting Information 
(Supplementary Fig. SI-1). The conversion of (-)-trans-CBDP to (-)-trans-Δ9-THCP using diverse Lewis’ acids, 
as already reported in the literature for the synthesis of the homolog Δ9-THC27–29, led to a complex mixture 
of isomers which resulted in an arduous and low-yield isolation of (-)-trans-Δ9-THCP by standard chroma-
tographic techniques. Therefore, for the synthesis of (-)-trans-Δ9-THCP, its regioisomer (-)-trans-Δ8-THCP 
was synthesized first by condensation of 5-heptylbenzene-1,3-diol with (1 S,4 R)-1-methyl-4-(prop-1-en-2-yl)
cycloex-2-enol, as described above, but the reaction was left stirring for 48 hours. Alternatively, (-)-trans-CBDP 
could be also quantitatively converted to (-)-trans-Δ8-THCP in the same conditions. Hydrochlorination of the 
Δ8 double bond of (-)-trans-Δ8-THCP, using ZnCl2 as catalyst, allowed to obtain (-)-trans-HCl-THCP, which was 
successively converted to (-)-trans-Δ9-THCP in 87% yield by selective elimination on position 2 of the terpene 
moiety using potassium t-amylate as base (Fig. 2a).
The chemical identification of synthetic (-)-trans-CBDP and (-)-trans-Δ9-THCP, and their unambiguous 
1H and 13C assignments were achieved by NMR spectroscopy (Supplementary Table SI-1,2 and Supplementary 
Fig. SI-2,3). Since (-)-trans-CBDP and (-)-trans-Δ9-THCP differ from the respective homologs (CBD, CBDB, 
CBDV, Δ9-THC, Δ9-THCB and Δ9-THCV) solely for the length of the alkyl chain on the resorcinyl moiety, no 
significant differences in the proton chemical shifts of the terpene and aromatic moieties were observed for CBD 
and Δ9-THC homologs. The perfect match in the chemical shift of the terpene and aromatic moieties between 
the synthesized (-)-trans-CBDP and (-)-trans-Δ9-THCP and the respective homologues11,24,30, combined with 
the mass spectra and fragmentation pattern, allowed us to unambiguously confirm the chemical structures of the 
two new synthetic cannabinoids. The trans (1R,6R) configuration at the terpene moiety was confirmed by optical 
rotatory power. The new cannabinoids (-)-trans-CBDP and (-)-trans-Δ9-THCP showed an [α]D20 of −145° and 
−166°, respectively, in chloroform. The [α]D20 values were in line with those of the homologs11,31, suggesting a 
Figure 1. UHPLC-HRMS identification of (-)-trans-CBDP and (-)-trans-Δ9-THCP. Extracted ion 
chromatograms (EIC) of CBDP and Δ9-THCP from a standard mixture at 25 and 10 ng/mL respectively (a) and 
from the native (red plot) and decarboxylated (black plot) FM2 (b). (c,d) Comparison of the high-resolution 
fragmentation spectra of synthetic and natural CBDP and Δ9-THCP in both positive (ESI+) and negative 
(ESI−) mode.
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(1R,6R) configuration for both CBDP and Δ9-THCP. A perfect superimposition between the 1H (Fig. 2b,e) and 
13C NMR spectra (Fig. 2c,f) and the circular dichroism absorption (Fig. 2d,g) of both synthetic and extracted 
(-)-trans-CBDP and (-)-trans-Δ9-THCP was observed, confirming the identity of the two new cannabinoids 
identified in the FM2 cannabis variety.
Binding affinity at human CB1 and cB2 receptors. The binding affinity of (-)-trans-Δ9-THCP 
against purified human CB1 and CB2 receptors was determined in a radioligand binding assay, using [3H]
CP55940 or [3H]WIN 55212-2 as reference compounds, and dose-response curves were determined (Fig. 3a,b). 
(-)-trans-Δ9-THCP binds with high affinity to both human CB1 and CB2 receptors with a Ki of 1.2 and 6.2 nM, 
respectively. (-)-trans-Δ9-THCP resulted 33-times more active than (-)-trans-Δ9-THC (Ki = 40 nM), 63-times 
Figure 2. Synthesis and spectroscopic characterization of (-)-trans-CBDP and (-)-trans-Δ9-THCP. (a) 
Reagents and conditions: (a) 5-heptylbenzene-1,3-diol (1.1 eq.), pTSA (0.1 eq.), CH2Cl2, r.t., 90 min.; (b) 
5-heptylbenzene-1,3-diol (1.1 eq.), pTSA (0.1 eq.), DCM, r.t., 48 h; (c) pTSA (0.1 eq.), DCM, r.t., 48 h; (d) ZnCl2 
(0.5 eq.), 4 N HCl in dioxane (1 mL per 100 mg of Δ8-THCP), dry DCM, argon, 0 °C to r.t., 2 h. (e) 1.75 M 
potassium t-amylate in toluene (2.5 eq.), dry toluene, argon, −15 °C, 1 h. (b–g) Superimposition of 1H, 13C NMR 
and CD spectra for natural (red line) and synthesized (blue line) (-)-trans-CBDP (b–d) and (-)-trans-Δ9-THCP 
(e–g).
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more active than (-)-trans-Δ9-THCV (Ki = 75.4 nM) and 13-times more active than the newly discovered 
(-)-trans-Δ9-THCB (Ki = 15 nM) against CB1 receptor12,14. Moreover, the new identified (-)-trans-Δ9-THCP 
resulted about 5- to 10-times more active against CB2 receptor (Ki = 6.2 nM), in contrast with (-)-trans-Δ9-THC, 
(-)-trans-Δ9-THCB and (-)-trans-Δ9-THCV, which instead showed a comparable binding affinity with a Ki rang-
ing from 36 to 63 nM (Fig. 3a)12,14.
The highest activity of (-)-trans-Δ9-THCP, compared to the shorter homologues, was investigated by dock-
ing calculation. The X-ray structure of the active conformation of hCB1 receptor in complex with the agonist 
AM11542 (PDB ID: 5XRA) was used as reference for docking since marked structural changes in the orthosteric 
ligand-binding site are observed in comparison with the conformation of the receptor bound to an antagonist32,33. 
AM11542 is a synthetic Δ8 cannabinoid with high affinity against hCB1 receptor (Ki = 0.11 nM) possessing a 
7′-bromo-1′,1′-dimethyl-heptyl aliphatic chain at C3 of the resorcinyl moiety. As expected, due to the close chem-
ical similarity, the predicted binding mode of (-)-trans-Δ9-THCP (Fig. 3c) reflected that of AM11542 in the CB1 
crystal structure (Fig. SI-6a,b)18. (-)-trans-Δ9-THCP bound in the active conformation of CB1 in an L-shaped 
pose. The tetrahydro-6H-benzo[c]chromene ring system is located within the main hydrophobic pocket delim-
ited by Phe174, Phe177, Phe189, Lys193, Pro269, Phe170, and Phe268. In particular, the aromatic ring of the 
resorcinyl moiety is involved in two edge-to-face π-π interactions with Phe170 and Phe268, whereas the phe-
nolic hydroxyl group at C1 is engaged in a H-bond with Ser383 (Fig. 3c). Interestingly, the heptyl chain at C3 
Figure 3. In vitro activity and docking calculation of Δ9-THCP. (a) Binding affinity (Ki) of the four homologues 
of Δ9-THC against human CB1 and CB2 receptors. (b) Dose-response studies of Δ9-THCP against hCB1 
(in blue) and hCB2 (in grey). All experiments were performed in duplicate and error bars denote s.e.m. of 
measurements. (c) Docking pose of (-)-trans-Δ9-THCP (blue sticks), in complex with hCB1 receptor (PDB ID: 
5XRA, orange cartoon). Key amino acidic residues are reported in orange sticks. H-bonds are reported in yellow 
dotted lines. Heteroatoms are color-coded: oxygen in red, nitrogen in blue and sulphur in yellow. (d) Binding 
pocket of hCB1 receptor, highlighting the positioning of the heptyl chain within the long hydrophobic channel 
of the receptor (yellow dashed line). The side hydrophobic pocket is bordered in magenta. Panels c and d were 
built using Maestro 10.3 of the Schrödinger Suite.
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extended into a long hydrophobic tunnel formed by Leu193, Val196, Tyr275, Iso271, Leu276, Trp279, Leu359, 
Phe379, and Met363 (Fig. 3c,d). Because the predicted pose of the tricyclic tetrahydrocannabinol ring system 
is conserved among the four THC homologs (Supplementary Fig. SI-7a–c), the length of the alkyl chain at C3 
of the resorcinyl moiety could account for the different binding affinity observed among the four cannabinoids. 
(-)-trans-Δ9-THCP (Fig. 3c) and (-)-trans-Δ9-THC (Supplementary Fig. SI-7a) share the same positioning 
of the alkyl ‘tail’ within the hydrophobic channel12,33,34. However, the long heptyl chain of Δ9-THCP is able to 
extend into the tunnel along its entire length, maximizing the hydrophobic interactions with the residues of the 
side channel. In contrast, the tunnel is only partially occupied by the shorter pentyl chain of (-)-trans-Δ9-THC, 
accounting for the higher affinity of Δ9-THCP (Ki = 1.2 nM) compared to Δ9-THC (Ki = 40 nM). A different 
positioning of the ‘tail’ was instead predicted for the shorter alkyl chain homologues, Δ9-THCV and Δ9-THCB. 
The propyl and butyl chain of Δ9-THCV and Δ9-THCB, respectively, are too short to effectively extend within 
the hydrophobic channel. As stated in our previous work12, these shorter chains accommodate within a small 
hydrophobic pocket delimitated by Phe200, Leu359, and Met363 (Supplementary Fig. SI–7b,c). This side pocket 
is located at the insertion between the main hydrophobic pocket and the long channel (Fig. 3d) and seems to 
accommodate small hydrophobic substituents (i.e. gem-dimethyl or cycloalkyl) introduced at C1′ position of the 
side chain of several synthetic cannabinoids, rationalizing the notable enhancement in potency and affinity for 
these derivatives35–39.
In vivo determination of the cannabinoid profile of Δ9-tHcp. The cannabinoid activity of Δ9-THCP 
was evaluated by the tetrad of behavioural tests on mice. The tetrad includes the assessment of spontaneous 
activity, immobility index (catalepsy), analgesia and changes in rectal temperature. Decrease of locomotor activ-
ity, catalepsy, analgesia and hypothermia are well-known signs of physiological manifestations of cannabinoid 
activity40. After intraperitoneal (i.p.) administration, Δ9-THCP at 2.5 mg/kg markedly reduced the spontaneous 
activity of mice in the open field, while at 5 and 10 mg/kg it induced catalepsy on the ring with the immobility 
as compared to the vehicle treated mice (Fig. 4b,c) (0 mg/kg: 6888 cm ± 474.8, 10 mg/kg: 166.8 cm ± 20.50, 5 mg/
kg: 127.5 cm ± 31.32, 2.5 mg/kg: 4072 cm ± 350.8, p = 0.0009). Moreover, Δ9-THCP administration induced 
a significant increase, at 10 and 5 mg/kg, in the latency for moving from the catalepsy bar (Fig. 4e) (0 mg/kg: 
15.20 sec ± 4.33, 10 mg/kg: 484.5 sec ± 51.58, 5 mg/kg: 493.4 sec ± 35.68, 2.5 mg/kg: 346.1 sec ± 35.24, p = 0.0051). 
In the hot plate test (Fig. 4f), Δ9-THCP (10 and 5 mg/kg) induced antinociceptive effect, whereas at 2.5 mg/kg 
there was a trend in the induction of antinociception, which resulted not statistically significant as compared to 
the vehicle treated mice (0 mg/kg: 19.20 sec ± 2.65, 10 mg/kg: 57.0 sec ± 2.0, 5 mg/kg: 54.38 sec ± 2.86, 2.5 mg/
kg: 40.22 sec ± 5.8, p = 0.0044). Δ9-THCP administration induced a dose dependent significant decrease, only 
Figure 4. Dose-dependent effects of Δ9-THCP administration (2.5, 5, or 10 mg/kg, i.p.) on the tetrad 
phenotypes in mice in comparison to vehicle. (a) Time schedule of the tetrad tests in minutes from Δ9-THCP 
or vehicle administration. (b,c) Locomotion decrease induced by Δ9-THCP administration in the open field 
test. (d) Decrease of body temperature after Δ9-THCP administration; the values are expressed as the difference 
between the basal temperature (i.e., taken before Δ9-THCP or vehicle administration) and the temperature 
measured after Δ9-THCP or vehicle administration. (e) Increase in the latency for moving from the catalepsy 
bar after Δ9-THCP administration. (f) Increase in the latency after the first sign of pain shown by the mouse 
in the hot plate test following Δ9-THCP administration. Data are represented as mean ± SEM of 5 mice per 
group. * indicate significant differences compared to 0 (vehicle injection), respectively. *p < 0.05, **p < 0.01, 
***p < 0.001 versus Δ9-THCP 0 mg/kg (vehicle). The Kruskall-Wallis test followed by Dunn’s post hoc 
tests were performed for statistical analysis.
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at 10 mg/kg, in body temperature as compared to vehicle (0 mg/kg: 0.40 °C ± 0.25, 10 mg/kg: −7.10 °C ± 0.43, 
5 mg/kg: −5.28 °C ± 0.36, 2.5 mg/kg: −4,12 °C ± 0.38, p = 0.0009) (Fig. 4d).
Semi-quantification of CBDP and Δ9-THCP in the FM2 extract. A semi-quantification method 
based on LC-HRMS allowed to provide an approximate amount of the two new phytocannabinoids in the FM2 
ethanol extract. Their pentyl homologues, CBD and Δ9-THC, showed a concentration of 56 and 39 mg/g respec-
tively, in accordance with the values provided by the Military Chemical Pharmaceutical Institute (59 mg/g and 
42 mg/g for CBD and Δ9-THC respectively), obtained by the official GC-FID quantitative method. The same 
semi-quantitative method provided an amount of about 243 and 29 µg/g for CBDP and Δ9-THCP respectively.
Discussion
Up to now, almost 150 phytocannabinoids have been detected in cannabis plant7,41,42, though most of them have 
neither been isolated nor characterized. The well-known CBD and Δ9-THC have been extensively characterized 
and proved to possess interesting pharmacological profiles43–47, thus the attention towards the biological activity 
of their known homologs like CBDV and Δ9-THCV has recently grown as evidenced by the increasing number 
of publications per year appearing on Scopus. Other homologs like those belonging to the orcinoid series are 
scarcely investigated likely due to their very low amount in the plant that makes their isolation very challenging. 
In recent years, the agricultural genetics research has made great progresses on the selection of rare strains that 
produce high amounts of CBDV, CBG and Δ9-THCV48–50, thus it would not be surprising to see in the near future 
cannabis varieties rich in other minor phytocannabinoids. This genetic selection would enable the production of 
extracts rich in a specific phytocannabinoid with a characteristic pharmacological profile. For this reason, it is 
important to carry out a comprehensive chemical profiling of a medicinal cannabis variety and a thorough inves-
tigation of the pharmacological activity of minor and less known phytocannabinoids.
As the pharmacological activity of Δ9-THC is particularly ascribed to its affinity for CB1 receptor, the litera-
ture suggests that the latter can be increased by elongating the alkyl side chain, which represents the main can-
nabinoid pharmacophoric driving force14. Therefore, taking THC as the lead compound, a series of cannabinoids 
have been chemically synthesized and their biological potency resulted several times higher than Δ9-THC itself15. 
To the best of our knowledge, naturally occurring cannabinoids with a linear alkyl side chain longer than five 
terms have never been detected or even putatively identified in cannabis plant. However, the cutting-edge techno-
logical platform of the Orbitrap mass spectrometry and the use of advanced analytical techniques like metabolo-
mics can enable the discovery and identification of new compounds with a high degree of confidence even when 
present in traces in complex matrices42,51. In the present work, we report for the first time the isolation and full 
characterization of two new CBD and Δ9-THC heptyl homologs, which we named cannabidiphorol (CBDP) and 
Δ9-tetrahydrocannabiphorol (Δ9-THCP), respectively. These common names were derived from the traditional 
naming of phytocannabinoids based on the resorcinyl residue, in this case corresponding to sphaerophorol.
The biological results obtained in the in vitro binding assay indicated an affinity for CB1 receptor more than 
thirty-fold higher compared to the one reported for Δ9-THC in the literature14. Also, this encouraging data was 
supported by in vivo evaluation of the cannabimimetic activity by the tetrad test, where Δ9-THCP decreased 
locomotor activity and rectal temperature, induced catalepsy and produced analgesia miming the properties of 
full CB1 receptor agonists (Fig. 4). In particular, Δ9-THCP proved to be as active as Δ9-THC but at lower doses. 
In fact, the minimum THC dose used in this kind of test is 10 mg/kg, whereas Δ9-THCP resulted active at 5 mg/
kg in three of the four tetrad tests. These results, accompanied by the docking data, are in line with the extensive 
structure-activity relationship (SAR) studies performed through the years on synthetic cannabinoids, revealing 
the importance of the length of the alkyl chain in position 3 on the resorcinyl moiety in modulating the ligand 
affinity at CB1 receptor.
Although the amount of the heptyl homologues of CBD and Δ9-THC in the FM2 variety could appear trifling, 
both in vitro and in vivo preliminary studies reported herein on Δ9-THCP showed a cannabimimetic activity 
several times higher than its pentyl homolog Δ9-THC. Moreover, it is reasonable to suppose that other cannabis 
varieties may contain even higher percentages of Δ9-THCP. It is also important to point out that there exists an 
astonishing variability of subject response to a cannabis-based therapy even with an equal Δ9-THC dose52–54. It 
is therefore possible that the psychotropic effects are due to other extremely active phytocannabinoids such as 
Δ9-THCP. However, up to now nobody has ever searched for this potent phytocannabinoid in medicinal cannabis 
varieties. In our opinion, this compound should be included in the list of the main phytocannabinoids to be deter-
mined for a correct evaluation of the pharmacological effect of the cannabis extracts administered to patients. In 
fact, we believe that the discovery of an extremely potent THC-like phytocannabinoid may shed light on several 
pharmacological effects not ascribable solely to Δ9-THC.
Ongoing studies are devoted to the investigation of the pharmacological activity of CBDP and to expand 
that of Δ9-THCP. It is known that CBD binds with poor affinity to both CB1 and CB2 receptors55. Therefore, 
the evaluation of the cannabimimetic activity of CBDP does not appear to be a high priority, although science 
can hold great surprises. Our current work is rather focused on testing its anti-inflammatory, anti-oxidant and 
anti-epileptic activity, which are typical of CBD46.
Methods
plant material. FM2 cannabis variety is obtained from the strain CIN-RO produced by the Council for 
Agricultural Research and Economics (CREA) in Rovigo (Italy) and provided to the Military Chemical 
Pharmaceutical Institute (MCPI, Firenze, Italy) for breeding. FM2 inflorescence (batch n. 6A32/1) was supplied 
by the MCPI with the authorization of the Italian Ministry of Health (prot. n. SP/062). The raw plant material 
(10 g) was finely grinded and divided into two batches: one batch (500 mg) was extracted with 50 mL of ethanol 
96% according to the procedure indicated by the monograph of Cannabis Flos of the German Pharmacopoeia56 
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and was analyzed by UHPLC-HESI-Orbitrap after proper dilution with acetonitrile (×100). The remaining 9.5 g 
were extracted following the protocol of Pellati et al. with some modifications26. Briefly, freeze-dried plant mate-
rial was extracted with 400 mL of n-hexane for 15 min under sonication in an ice bath. Samples were centrifuged 
for 10 min at 2000 × g and the supernatants collected. The procedure was repeated twice more on the pellets. 
The combined supernatants were then dried under reduced pressure and resuspended in 10 mL of acetonitrile, 
filtered and used for the isolation of CBDPA and THCPA by semi-preparative liquid chromatography.
Isolation of natural CBDP and Δ9-tHcp. Aliquots (1 mL) of the solution obtained as described in the 
‘Plant Material’ section were injected in a semi-preparative LC system (Octave 10 Semba Bioscience, Madison, 
USA). The chromatographic conditions used are reported in the paper by Citti et al.11. The column employed was 
a Luna C18 with a fully porous silica stationary phase (Luna 5 µm C18(2) 100 Å, 250 × 10 mm) (Phenomenex, 
Bologna, Italy) and a mixture of acetronitrile:0.1% aqueous formic acid 70:30 (v/v) was used as mobile phase 
at a flow rate of 5 mL/min. CBDPA and THCPA (retention time 19.0 min and 75.5 min respectively) were 
isolated as reported in our previous work11. The fractions containing CBDPA and THCPA were analyzed by 
UHPLC-HESI-Orbitrap. The fractions containing predominantly either one or the other cannabinoid were sep-
arately combined and dried on the rotavapor at 70 °C. Each residue was subject to decarboxylation at 120 °C for 
two hours in oven. An amount of about 0.6 mg of CBDP and about 0.3 mg of Δ9-THCP was obtained.
UHpLc-HeSi-orbitrap metabolomic analysis. FM2 extracts were analyzed on a Thermo Fisher 
Scientific Ultimate 3000 system equipped with a vacuum degasser, a binary pump, a thermostated autosampler, 
a thermostated column compartment and interfaced to a heated electrospray ionization source and a Q-Exactive 
Orbitrap mass spectrometer (UHPLC-HESI-Orbitrap). The parameters of the HESI source were set according to 
Citti et al.11: capillary temperature, 320 °C; vaporizer temperature, 280 °C; electrospray voltage, 4.2 kV (positive 
mode) and 3.8 kV (negative mode); sheath gas, 55 arbitrary units; auxiliary gas, 30 arbitrary units; S lens RF level, 
45. Analyses were acquired using the Xcalibur 3.0 software (Thermo Fisher Scientific, San Jose, CA, USA) in full 
scan data-dependent acquisition (FS-dd-MS2) in positive (ESI+) and negative (ESI−) mode at a resolving power 
of 70,000 FWHM at m/z 200. A scan range of m/z 250–400, an AGC of 3e6, an injection time of 100 ms and an 
isolation window for the filtration of the precursor ions of m/z 0.7 were chosen as the optimal parameters for the 
mass analyzer. A normalized collision energy (NCE) of 20 was used to fragment the precursor ions. Extracted 
ion chromatograms (EIC) of the [M + H]+ and [M-H]− molecular ions were derived from the total ion chroma-
togram (TIC) of the FM2 extracts and matched with pure analytical standards for accuracy of the exact mass (5 
ppm), retention time and MS/MS spectrum.
The chromatographic separation was carried out on a Poroshell 120 SB-C18 (3.0 × 100 mm, 2.7 µm, Agilent, 
Milan, Italy) following the conditions employed for our previous work11.
A semi-quantitative analysis of Δ9-THC and CBD and their heptyl analogs CBDP and Δ9-THCP was achieved 
using a calibration curve with an external standard. A stock solution of CBD and Δ9-THC, CBDP and Δ9-THCP 
(1 mg/mL) was properly diluted to obtain five non-zero calibration points at the final concentrations of 50, 100, 
250, 500, and 1000 ng/mL for CBD and Δ9-THC and of 1, 5, 10, 25, and 50 ng/mL for CBDP and Δ9-THCP. A 
standard solution of Δ9-THC-d3 was added at each calibration standard at a final concentration of 50 ng/mL. 
The linearity was assessed by the coefficient of determination (R2), which was greater than 0.993 for each analyte.
Synthetic procedure. All reagents and solvents were employed as purchased without further purification 
unless otherwise specified. The following abbreviations for common organic solvents have been used herein: 
diethyl ether (Et2O); dichloromethane (DCM); cyclohexane (CE). Reaction monitoring was performed by 
thin-layer chromatography on silica gel (60F-254, E. Merck) and checked by UV light, or alkaline KMnO4 aque-
ous solution57–59. Reaction products were purified, when necessary, by flash chromatography on silica gel (40−63 
μm) with the solvent system indicated. NMR spectra were recorded on a Bruker 400 or Bruker 600 spectrom-
eter working respectively at 400.134 MHz and 600.130 MHz for 1H and at 100.62 MHz or 150.902 MHz for 13C. 
Chemical shifts (δ) are in parts per million (ppm) and they were referenced to the solvent residual peaks (CDCl3 
δ = 7.26 ppm for proton and δ = 77.20 ppm for carbon); coupling constants are reported in hertz (Hz); splitting 
patterns are expressed with the following abbreviations: singlet (s), doublet (d), triplet (t), quartet (q), double dou-
blet (dd), quintet (qnt), multiplet (m), broad signal (b). Monodimensional spectra were acquired with a spectral 
width of 8278 Hz (for 1H-NMR) and 23.9 kHz (for 13C-NMR), a relaxation delay of 1 s, and 32 and 1024 number 
of transients for 1H-NMR and 13C-NMR, respectively12. The COSY spectra were recorded as a 2048 × 256 matrix 
with 2 transients per t1 increment and processed as a 2048 × 1024 matrix; the HSQC spectra were collected as a 
2048 × 256 matrix with 4 transients per t1 increment and processed as a 2048 × 1024 matrix, and the one-bond 
heteronuclear coupling value was set to 145 Hz; the HMBC spectra were collected as a 4096 × 256 matrix with 16 
transients per t1 increment and processed as a 4096 × 1024 matrix, and the long-range coupling value was set to 8 
Hz12. Circular dichroism (CD) and UV spectra were acquired on a Jasco (Tokyo, Japan) J-1100 spectropolarime-
ter using a 50 nm/min scanning speed. Quartz cells with a 10 mm path length were employed to record spectra in 
the 500–220 nm range12. Optical rotation (λ) was measured with a Polarimeter 241 (cell-length 100 mm, volume 
1 mL) from Perkin-Elmer (Milan, Italy). The synthetic procedures described below were adjusted from previously 
published works12,57.
Synthesis of (1′R,2′R)-4-heptyl-5′-methyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-2,6-diol, 
(-)-trans-CBDP
(1 S,4 R)-1-methyl-4-(prop-1-en-2-yl)cycloex-2-enol (146 mg, 0.96 mmol, 0.9 eq.), solubilized in 15 mL of 
anhydrous DCM, was added over a period of 20 min to a stirred solution of 5-heptylbenzene-1,3-diol (222 mg, 
1.07 mmol, 1 eq.) and p-toluenesulfonic acid (20 mg, 0.11 mmol, 0.1 eq.) in anhydrous DCM (15 mL) at room 
temperature and under a positive pressure of argon. After stirring in the same conditions for 1 h, the reaction was 
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quenched with 10 mL of a saturated aqueous solution of NaHCO3. The mixture was partitioned between Et2O and 
water. The organic layer was separated and washed with brine, dried with anhydrous Na2SO4 and evaporated. The 
residue was chromatographed (ratio crude:silica 1/120, eluent: CE:DCM 8/2). All the chromatographic fractions 
were analyzed by HPLC-UV and UHPLC-HESI-Orbitrap and only the fractions containing exclusively CBDP 
were concentrated to give 76 mg of a colorless oil (23% yield, purity > 99%).
1H NMR (400 MHz, CDCl3) δ 6.10–6.30 (m, 2 H), 5.97 (bs, 1 H), 5.57 (s, 1 H), 4.66 (s, 1 H), 4.66 (bs, 1 H), 4.56 
(s, 1 H), 3.89–3.81 (m, 1 H), 2.52–2.35 (m, 3 H), 2.24 (td, J = 6.1, 12.7 Hz, 1 H), 2.09 (ddt, J = 2.4, 5.1, 17.9 Hz, 1 H), 
1.89–1.74 (m, 5 H), 1.65 (s, 3 H), 1.55 (qnt, J = 7.6 Hz, 2 H), 1.28 (td, J = 4.7, 8.2, 9.0 Hz, 8 H), 0.87 (t, J = 6.7 Hz, 
3 H). 13C NMR (101 MHz, CDCl3) δ 156.27, 154.09, 149.56, 143.23, 140.22, 124.30, 113.93, 111.01, 109.91, 108.26, 
46.33, 37.46, 35.70, 31.99, 31.14, 30.59, 29.43, 29.35, 28.60, 23.86, 22.84, 20.71, 14.29. HRMS m/z [M + H]+ 
calcd. for C23H35O2+: 343.2632. Found: 343.2629; [M-H]− calcd. for C23H33O2−: 341.2475. Found: 341.2482. 
[α]D20 = −146° (c 1.0, ACN).
Synthesis of (6aR,10aR)-3-heptyl-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol, 
(-)-trans-Δ8-THCP
The set-up of the reaction for the synthesis of (-)-trans-Δ8-THCP was performed as described for 
(-)-trans-CBDP and the resulting mixture was stirred at room temperature for 48 h. The mixture was diluted with 
Et2O, and washed with a saturated solution of NaHCO3 (10 mL). The organic layer was collected, washed with 
brine, dried (anhydrous Na2SO4) and concentrated. After purification over silica gel (ratio crude:silica 1/150, 
eluent: CE:Et2O 95/5) 315 mg of a colorless oil (46% yield) were obtained.
1H NMR (400 MHz, CDCl3) δ 6.28 (d, J = 1.6 Hz, 1 H), 6.10 (d, J = 1.6 Hz, 1 H), 5.46–5.39 (m, 1 H), 4.78 (s, 
1 H), 3.20 (dd, J = 4.5, 16.0 Hz, 1 H), 2.70 (td, J = 4.7, 10.8 Hz, 1 H), 2.44 (td, J = 2.3, 7.4 Hz, 2 H), 2.21–2.10 (m, 
1 H), 1.92–1.76 (m, 3 H), 1.70 (s, 3 H), 1.63–1.52 (m, 2 H), 1.38 (s, 3 H), 1.30 (tt, J = 4.3, 9.4, 11.8 Hz, 8 H), 1.11 (s, 
3 H), 0.88 (t, J = 7.0 Hz, 3 H).
Synthesis of (6aR,10aR)-3-heptyl-9-chloro-6,6,9-trimethyl-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-
1-ol (HCl-THCP)
1 N ZnCl2 in Et2O (440 µL, 0.44 mmol, 0.5 eq.) was added to a stirred solution of Δ8-THCP (300 mg, 
0.87 mmol, 1 eq.) in 20 mL of anhydrous DCM, at room temperature and under nitrogen atmosphere. After 
30 min, the reaction was cooled at 0 °C and 2 mL of 4 N HCl in dioxane was added. The resulting mixture was 
stirred at room temperature, overnight and then diluted with Et2O. The organic layer was collected and washed, in 
sequence, with an aqueous saturated solution of NaHCO3 and brine. After dehydration with anhydrous Na2SO4, 
the organic phase was concentrated to give 305 mg (93% yield) of a yellowish oil, pure enough to be used in the 
next step without further purification.
1H NMR (400 MHz, CDCl3) δ 6.24 (d, J = 1.7 Hz, 1 H), 6.07 (d, J = 1.6 Hz, 1 H), 4.94 (s, 1 H), 3.45 (dd, J = 2.9, 
14.4 Hz, 1 H), 3.05 (td, J = 2.9, 11.3 Hz, 1 H), 2.42 (td, J = 1.5, 7.4 Hz, 2 H), 2.20–2.12 (m, 1 H), 1.80–1.71 (m, 
1 H), 1.66 (s, 4 H), 1.60–1.51 (m, 2 H), 1.49–1.42 (m, 1 H), 1.38 (s, 3 H), 1.34–1.18 (m, 10 H), 1.13 (s, 3 H), 0.87 (t, 
J = 6.6 Hz, 3 H). ESI-MS m/z [M + H] + calcd. for C23H3635[Cl]O2+: 379.2. Found: 379.4. Calcd. for C23H3637[Cl]
O2+: 381.2. Found: 381.3.
Synthesis of (6aR,10aR)-3-heptyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol, 
(-)-trans-Δ9-THCP.
HCl-THCP (305 mg, 0.82 mmol, 1 eq.) was solubilized in 10 mL of anhydrous toluene and cooled at −15 °C. 
1.75 N potassium t-amylate in toluene (1.17 mL, 2.05 mmol, 2.5 eq.) was added dropwise with a syringe to the first 
solution under a positive pressure of argon. The mixture was stirred in the same condition for 15 min and then at 
60 °C for 1 h. After cooling at room temperature, the reaction was quenched with a 1% solution of ascorbic acid 
and diluted with Et2O. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated. 
The residue was chromatographed (ratio crude/silica 1:300, hexane:i-propyl ether 9/1) to give 232 mg of a green-
ish oil (83% yield). 50 mg of (-)-trans-Δ9-THCP were further purified by semipreparative HPLC to prepare a pure 
analytic standard (purity > 99.9%).
1H NMR (600 MHz, CDCl3) δ 6.30 (t, J = 2.0 Hz, 1 H), 6.27 (d, J = 1.6 Hz, 1 H), 6.14 (d, J = 1.5 Hz, 1 H), 4.75 (s, 
1 H), 3.20 (dt, J = 2.5, 10.8 Hz, 1 H), 2.43 (dd, J = 6.4, 8.9 Hz, 2 H), 2.22–2.11 (m, 2 H), 1.97–1.87 (m, 1 H), 1.69–
1.65 (m, 4 H), 1.58–1.50 (m, 2 H), 1.43–1.37 (m, 4 H), 1.34–1.21 (m, 8 H), 1.09 (s, 3 H), 0.87 (t, J = 6.6 Hz, 3 H). 13C 
NMR (151 MHz, CDCl3) δ 154.97, 154.34, 143.02, 134.59, 123.92, 110.30, 109.22, 107.72, 77.38, 46.01, 35.72, 33.78, 
31.99, 31.37, 31.16, 29.50, 29.38, 27.77, 25.22, 23.55, 22.87, 19.47, 14.29. HRMS m/z [M + H]+ calcd. for C23H35O2+: 
343.2632. Found: 343.2633; [M-H]− calcd. for C23H33O2−: 341.2475. Found: 341.2481. [α]D20 = −166° (c 1.0, ACN).
Binding at cB1 and cB2 Receptors. The binding affinity of (-)-trans-Δ9-THCP against human CB1 and 
CB2 receptors was assessed by Eurofins Discovery using a radioligand binding assay. Ten concentrations of the 
phytocannabinoid from 1 nM to 30 µM were tested in duplicate. [3H]CP55940 (at 2 nM, Kd = 2.4 nM) and [3H]
WIN 55212-2 (at 0.8 nM, Kd = 1.5 nM) were used as specific radioligand for hCB1 and hCB2, respectively60,61. 
Equation 1 was employed to calculate the percent inhibition (%in) of control specific binding obtained in the 












A non-linear regression analysis of the competition curves generated with mean replicate values (Eq. 2) was 
used to calculate the IC50 values (concentration causing a half-maximal inhibition of control specific binding)62.
























Where Y is the specific binding, A is the left asymptote of the curve, D is the right asymptote f the curve, C is the 
compound concentration, C50 is the IC50 value and nH is the slope factor. This analysis was carried out using a 
software developed at Cerep (Hill software) and validated by comparing the data with that generated by the com-
mercial software SigmaPlot 4.0 for Windows (1997 by SPSS Inc.). The inhibition constants (Ki) were determined 









where L is the concentration of the radioligand, and KD is the affinity of the radioligand for the receptor.
The data obtained for CP 55940 (CB1 IC50 = 1.7 nM, CB1 Ki = 0.93 nM) and WIN 55212-2 (CB2 IC50 = 2.7 nM, 
CB2 Ki = 1.7 nM) were in accordance with the values reported in literature60,61.
Docking simulation. The prediction of the binding mode of Δ9-THCP in complex with human CB1 recep-
tor was performed using Maestro 10.3 of the Schrödinger Suite63. The crystallographic structure of the active con-
formation of CB1 in complex with AM11542 (PDB ID: 5XRA) was downloaded from the Protein Data Bank and 
was used as reference for docking calculation. The protein was prepared using the Protein Preparation Wizard 
module64. The chemical structure of (-)-trans-Δ9-THCP was sketched with ChemDraw 12.0 and converted from 
2D to 3D with the LigPrep utility65. Five conformations per ligand were initially generated, and appropriate ion-
ization state and tautomers were evaluated for each conformation at physiological pH66,67. Afterwards, ligand 
conformations were minimized with the OPLS_2005 force field. Rigid docking was performed in extra precision 
mode with Glide version 6.868.
tetrad test. Male C57BL6/J mice (7 weeks old; n = 5) were treated with Δ9-THCP (10, 5 and 2.5 mg/kg) or 
vehicle (1:1:18; ethanol:Kolliphor EL:0.9% saline) by i.p. administration. Mice were evaluated for hypomotility 
(open field test), hypothermia (body temperature), antinociceptive (hot plate test), and cataleptic (bar test) effects, 
using the procedures of the tetrad tests as reported by Metna-Laurent et al.69. The same animals were used in all 
four behavioral tests. Statistical analysis was performed using the Kruskall-Wallis test and Dunn’s post hoc tests.
Body temperature. The mouse was immobilized and the probe gently inserted for 1 cm into the rectum 
until stabilization of temperature. Between each mouse the probe was cleaned with 70% ethanol and dried with 
paper towel.
Open field. The open field test was used for the evaluation of motor activity. Behavioral assays were per-
formed 30 min after drug (or vehicle) injection. The apparatus was cleaned before each behavioral session by a 
70% ethanol solution. Naϊve mice were randomly assigned to a treatment group. Behaviors were recorded, stored, 
and analyzed using an automated behavioral tracking system (Smart v3.0, Panlab Harvard Apparatus). Mice were 
placed in an OFT arena (l × w × h: 44 cm × 44 cm × 30 cm), and ambulatory activity (total distance travelled in 
centimeter) was recorded for 15 min and analyzed.
Bar test. The bar test was used for the evaluation of catalepsy. The bar was a 40 cm in length and 0.4 cm in 
diameter glass rod, which was horizontally elevated by 5 cm above the surface. Both forelimbs of the mouse were 
positioned on the bar and its hind legs on the floor of the cage, ensuring that the mouse was not lying down on 
the floor. The chronometer was stopped when the mouse descended from the bar (i.e., when the two forepaws 
touched the floor) or when 10 min had elapsed (i.e., cut-off time). Catalepsy was measured as the time duration 
each mouse held the elevated bar by both its forelimbs (latency for moving in seconds).
Hot plate. The hot plate test was performed to assess changes in the nociception. On the day of the experi-
ment each mouse was placed on a hot plate (Ugo Basile) that was kept at a constant temperature of 52 °C. Licking 
of the hind paws or jumping were considered as a nociceptive response (NR) and the latency was measured in 
seconds 85 minutes after drug or vehicle administration, taking a cut-off time of 30 or 60 s in order to prevent 
tissue damage.
Animals. Male C57BL/6 mice (Charles River, Italy) of 18–20 g weight were used for the tetrad experiments. A 
12 h light/dark cycle with light on at 6:00 A.M., a constant temperature of 20–22 °C, and a 55–60% humidity were 
maintained for at least 1 week before beginning the experiments. Mice were housed three per cage with chow 
and tap water available ad libitum. The experimental procedures employed for the work presented herein were 
approved by the Animal Ethics Committee of the University of Campania “L. Vanvitelli”, Naples. Animal care and 
welfare were entrusted to adequately trained personnel in compliance with Italian (D.L. 116/92) and European 
Commission (O.J. of E.C. L358/1, 18/12/86) regulations on the protection of animals used for research purposes. 
All efforts were made to minimize animal numbers and avoid unnecessary suffering during the experiments.
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